- Home
- PLRX vs FENC Comparison
PLRX vs FENC Comparison
Compare PLRX & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- FENC
- Stock Information
- Founded
- PLRX 2015
- FENC 1996
- Country
- PLRX United States
- FENC United States
- Employees
- PLRX N/A
- FENC N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLRX Health Care
- FENC Health Care
- Exchange
- PLRX Nasdaq
- FENC Nasdaq
- Market Cap
- PLRX 165.5M
- FENC 156.9M
- IPO Year
- PLRX 2020
- FENC 2001
- Fundamental
- Price
- PLRX $3.08
- FENC $6.65
- Analyst Decision
- PLRX Buy
- FENC Strong Buy
- Analyst Count
- PLRX 10
- FENC 2
- Target Price
- PLRX $14.86
- FENC $14.00
- AVG Volume (30 Days)
- PLRX 3.4M
- FENC 53.9K
- Earning Date
- PLRX 02-26-2025
- FENC 03-20-2025
- Dividend Yield
- PLRX N/A
- FENC N/A
- EPS Growth
- PLRX N/A
- FENC N/A
- EPS
- PLRX N/A
- FENC N/A
- Revenue
- PLRX N/A
- FENC $49,348,000.00
- Revenue This Year
- PLRX N/A
- FENC $170.43
- Revenue Next Year
- PLRX N/A
- FENC $6.70
- P/E Ratio
- PLRX N/A
- FENC N/A
- Revenue Growth
- PLRX N/A
- FENC 278.09
- 52 Week Low
- PLRX $2.43
- FENC $3.96
- 52 Week High
- PLRX $18.00
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- PLRX 22.51
- FENC 58.24
- Support Level
- PLRX $2.92
- FENC $6.57
- Resistance Level
- PLRX $3.16
- FENC $6.96
- Average True Range (ATR)
- PLRX 0.85
- FENC 0.26
- MACD
- PLRX -0.39
- FENC -0.02
- Stochastic Oscillator
- PLRX 6.22
- FENC 61.25
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.